리메드

302550KOSDAQ의료용 기기 제조업

45.5 / 100

Reference Date: 2026-04-13

Financial Score12.0 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, PER raises overvaluation concerns. Slightly down 4.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Remed is a company specializing in developing and manufacturing medical devices that utilize non-invasive magnetic stimulation technology to treat various conditions such as depression, stroke, and chronic pain. Its key products, BrainStim and ALTMS, have received FDA and KFDA certifications for depression treatment and are expanding globally. The company also offers chronic pain management through NMS and aesthetic services via CSMS.

Number of Employees

114people

Average Salary

46.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

177.65Industry Average 26.520.0Point

6.7x industry avg (risky)

PBR

2.37Industry Average 1.702.5Point

Higher than industry avg (caution)

ROE

-0.09Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

12.60Industry Average 10.952.0Point

Higher than industry avg (caution)

Trend 2023~20257.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲16.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲52.0% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 3,020Won52-week high 3,98552-week low 2,755

1-month return2.0Point

1m -4.88% (slight drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
Neutral주식등의대량보유상황보고서(일반)2026-04-03
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral주식등의대량보유상황보고서(일반)2026-03-27